Werewolf Therapeutics to Merge with Ambros, Raises $150M in Oversubscribed Placement
HOWL has more than doubled off its 52-week low of $0.27 on elevated volume (38× avg).
Summary
Werewolf Therapeutics and Ambros Therapeutics announced a merger agreement, accompanied by a concurrent oversubscribed $150M private placement. The merger terms value Ambros at $500M and Werewolf at $47.5M, with post-merger ownership of 71.7% by Ambros, 21.5% by PIPE investors, and 6.8% by Werewolf. Termination fees are $20M payable by Ambros and $1.9M by Werewolf, and Werewolf stockholders receive one CVR per share for legacy assets WTX-124 and WTX-330. This is a transformative event for Werewolf, which had a market cap of only ~$21M and a going concern warning as of its last 10-Q. The merger likely brings new assets and the private placement provides substantial capital, addressing the company's cash runway and Nasdaq delisting risk. The oversubscription signals strong investor demand. This follows a series of insider and institutional selling, but the merger and financing could reverse the negative sentiment. Watch for details on the combined entity's pipeline and the closing conditions.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The 8-K details the merger terms: Ambros valued at $500M, Werewolf at $47.5M; post-merger ownership 71.7% Ambros, 21.5% PIPE investors, 6.8% Werewolf. Termination fees: $20M payable by Ambros, $1.9M by Werewolf. Werewolf stockholders receive one CVR per share for legacy assets WTX-124 and WTX-330.
At the time of this announcement, HOWL was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21M. The 52-week trading range was $0.27 to $2.38. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.